Detalles de la búsqueda
1.
Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
Kidney Int
; 105(6): 1291-1305, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537677
2.
Itaconate reduces proliferation and migration of fibroblast-like synoviocytes and ameliorates arthritis models.
Clin Immunol
; 264: 110255, 2024 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38763433
3.
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
Rheumatology (Oxford)
; 63(3): 772-779, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307082
4.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford)
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38460548
5.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Diabetes Obes Metab
; 26(3): 961-970, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073422
6.
Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis.
Cereb Cortex
; 33(13): 8342-8351, 2023 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37005068
7.
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes.
Endocr J
; 71(4): 403-408, 2024 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403638
8.
Positive association between proinsulin and fatty liver index in people with type 2 diabetes.
Endocr J
; 71(2): 193-197, 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38123335
9.
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Endocr J
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38658349
10.
Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) using a Japanese claims database.
Mod Rheumatol
; 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581672
11.
Subtle Radiographic Progression at Six Months Can Be Detected Using Automated Quantitative Software in Rheumatoid Arthritis While Receiving Tocilizumab.
Mod Rheumatol
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38753311
12.
Intravenous immunoglobulin treatment for obstetric antiphospholipid syndrome refractory to conventional therapy: A single-arm, open-labelled multicentre clinical trial.
Mod Rheumatol
; 34(3): 515-522, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340865
13.
Predictors of damage accrual in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A nationwide prospective study.
Mod Rheumatol
; 34(2): 382-390, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988333
14.
Development of quality indicators for pregnancy and childbirth in patients with systemic lupus erythematosus.
Mod Rheumatol
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38590037
15.
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Mod Rheumatol
; 34(2): 272-286, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405710
16.
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study.
Lab Invest
; 103(6): 100147, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37044248
17.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699654
18.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696589
19.
2023 ACR/EULAR antiphospholipid syndrome classification criteria.
Ann Rheum Dis
; 82(10): 1258-1270, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37640450
20.
Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.
Rheumatology (Oxford)
; 62(7): 2550-2555, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36458921